Market Overview
The vascular closure device market was valued at USD 1.77 billion in 2024 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.65% during the forecast period.
| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2020-2023 |
| Base Year |
2024 |
| Forecast Period |
2025-2032 |
| Vascular Closure Device Market Size 2024 |
USD 1.77 Billion |
| Vascular Closure Device Market, CAGR |
7.65% |
| Vascular Closure Device Market Size 2032 |
USD 3.2 Billion |
The vascular closure device market is dominated by leading players such as Teleflex Incorporated, Terumo Medical Corporation, Abbott, Haemonetics, Medtronic, Cardinal Health, Boston Scientific Corporation, Merit Medical, Cook Medical, and Meril Life. These companies focus on advancing closure technologies, expanding product portfolios, and enhancing global presence through strategic collaborations. North America held over 40% of the market share in 2024, driven by high cardiovascular procedure volumes, favorable reimbursement, and strong adoption of minimally invasive devices. Europe accounted for nearly 30%, supported by advanced hospital infrastructure and strict regulatory compliance, while Asia-Pacific captured close to 20%, emerging as the fastest-growing region due to rising healthcare investments and increasing patient access to interventional cardiology.
Market Insights
- The vascular closure device market was valued at USD 1.77 billion in 2024 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.65% during the forecast period.
- Rising prevalence of cardiovascular diseases and growing adoption of minimally invasive procedures drive strong demand for vascular closure devices, with passive approximators holding over 55% share in 2024.
- Key trends include the rapid adoption of bioabsorbable closure devices, integration with imaging systems for precise deployment, and rising focus on same-day discharge protocols to improve patient throughput.
- The competitive landscape features major players such as Teleflex, Abbott, Terumo, Medtronic, and Boston Scientific, focusing on innovation, partnerships, and global expansion to enhance market penetration.
- North America leads with over 40% share, followed by Europe at nearly 30% and Asia-Pacific at close to 20%, which is the fastest-growing region due to rising healthcare investments and procedural volumes.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Download Sample
Market Segmentation Analysis:
By Product
Passive approximators dominated the vascular closure device market in 2024, accounting for over 55% of total share. Their popularity is driven by ease of use, cost-effectiveness, and compatibility with a wide range of vascular procedures. These devices are preferred in routine diagnostic angiography and interventional cardiology due to minimal training requirements and shorter hemostasis times. Growing adoption of minimally invasive procedures and rising emphasis on patient comfort are boosting demand. Active approximators are gaining traction with their ability to provide faster closure and lower complication rates, particularly in high-risk patients undergoing complex interventions.
- For instance, Abbott Laboratories’ Perclose ProGlide suture-mediated closure system is a widely used active vascular closure device that has been demonstrated in some studies to significantly reduce the time to hemostasis and ambulation compared to manual compression, though average times can vary based on procedure and vessel size.
By Application
Cardiac interventions led the market, capturing nearly 60% share in 2024, supported by rising prevalence of coronary artery disease and increasing percutaneous coronary interventions (PCI) worldwide. The growing use of transcatheter aortic valve replacement (TAVR) procedures is also fueling segment growth. Vascular closure devices improve patient outcomes by reducing access-site complications and enabling faster ambulation, which is crucial for cardiac patients. Cerebrovascular and peripheral vascular interventions are expanding steadily, driven by increasing adoption of neuroendovascular procedures and peripheral artery disease treatments. Ongoing advancements in imaging and catheterization techniques support wider application adoption.
- For instance, Terumo Corporation, a leading manufacturer of vascular closure devices (VCDs) like the Angio-Seal, contributes to the overall market for procedures such as cardiac PCI. The Angio-Seal system is designed to achieve rapid hemostasis at femoral arterial puncture sites for diagnostic and interventional procedures using smaller sheaths, supporting faster patient ambulation and same-day discharge.
By End Use
Hospitals and clinics accounted for over 65% market share in 2024, making them the dominant end-use segment. High patient footfall, availability of skilled interventional cardiologists, and advanced catheterization labs drive demand for vascular closure devices in hospital settings. These facilities perform the majority of coronary angioplasty, diagnostic catheterization, and endovascular procedures, which require reliable closure solutions. Ambulatory surgical centers are witnessing significant growth as healthcare shifts toward outpatient procedures, offering cost efficiency and shorter recovery times. Cardiac catheterization laboratories also contribute notably, with increased focus on same-day discharge protocols and patient throughput optimization.
Key Growth Drivers
Rising Prevalence of Cardiovascular Diseases
The increasing burden of cardiovascular diseases is a major driver of vascular closure device demand. Rising cases of coronary artery disease and peripheral artery disease have led to a higher volume of percutaneous coronary interventions (PCI) and angiographic procedures. Vascular closure devices improve patient safety by reducing complications like bleeding and hematoma formation. Growing preference for minimally invasive procedures and early patient discharge further strengthens adoption. Hospitals and cardiac centers are rapidly integrating closure devices to support faster recovery and improve overall clinical outcomes.
- For instance, Haemonetics has marketed its VASCADE system, which has been shown in clinical trials, such as the AMBULATE trial, to enable faster patient ambulation and discharge times. The AMBULATE trial, specifically, showed the VASCADE MVP system reduced time to ambulation by 64% in electrophysiology procedures.
Technological Advancements in Device Design
Continuous innovation in vascular closure device technology is driving market growth. Modern devices offer faster hemostasis, reduced manual compression requirements, and improved patient comfort. Active approximators with bioabsorbable materials are gaining popularity due to their ability to provide secure closure and minimize long-term complications. Manufacturers are focusing on developing next-generation devices with simplified deployment systems to reduce operator dependency and procedural time. These improvements are boosting acceptance among interventional cardiologists and vascular surgeons, thereby increasing usage across diagnostic and interventional procedures worldwide.
- For instance, Teleflex Incorporated’s MANTA large-bore vascular closure device, approved by the FDA in 2019, features a fully bioresorbable collagen plug and achieves a median hemostasis time of 24 seconds, with a major complication rate of 5.3% reported in its clinical trials. Its design enhances operator ease and patient outcomes.
Shift Toward Outpatient and Same-Day Procedures
The healthcare sector is witnessing a rapid shift toward outpatient care and same-day discharge models. Ambulatory surgical centers and catheterization labs are expanding their procedural capabilities to reduce hospital stay durations and overall treatment costs. Vascular closure devices play a key role in supporting these models by ensuring rapid hemostasis and enabling early patient mobilization. Their ability to reduce post-procedure observation time aligns with value-based care initiatives, encouraging higher adoption rates. This trend is particularly strong in developed markets with rising demand for cost-effective care.
Key Trends & Opportunities
Adoption of Bioabsorbable Closure Devices
The industry is witnessing a growing shift toward bioabsorbable closure technologies. These devices eliminate the need for device removal, reduce foreign body reactions, and improve long-term safety outcomes. Growing preference for absorbable implants in cardiovascular procedures is creating opportunities for manufacturers to introduce innovative solutions. Several companies are investing in research and clinical trials to enhance product efficacy, which is expected to expand the market over the forecast period and attract healthcare providers seeking improved patient outcomes and lower complication rates.
- For instance, Vivasure Medical received CE mark approval in April 2025 for its PerQseal Elite bioabsorbable vascular closure system, which uses a fully absorbable synthetic patch implant that is fully absorbed within approximately 180 days.
Integration with Imaging and Navigation Systems
Technological integration with imaging and vascular navigation systems is emerging as a key trend. Real-time imaging during device deployment enhances precision, minimizes procedural errors, and improves operator confidence. Hybrid catheterization labs adopting image-guided vascular closure are likely to drive product demand further. Opportunities exist for manufacturers to develop devices compatible with robotic-assisted interventions and advanced fluoroscopic systems. This trend aligns with the growth of complex endovascular procedures, supporting safer and more efficient patient care globally.
- For instance, Medtronic released its Evolut FX+ TAVR system in March 2024, which was designed with larger windows to facilitate coronary access during complex procedures.
Key Challenges
Risk of Access Site Complications
Despite technological improvements, vascular closure devices carry risks such as infection, vessel injury, or device failure. These complications may lead to additional interventions, extended hospital stays, and higher treatment costs. Concerns over safety can limit adoption, particularly in low-volume centers with limited experience. Manufacturers must invest in training programs and post-market surveillance to address these risks and improve clinical outcomes. Regulatory bodies are also increasing scrutiny of device safety, requiring robust clinical data before product approvals.
High Product Costs and Reimbursement Barriers
The relatively high cost of vascular closure devices can be a barrier, especially in price-sensitive markets. Limited reimbursement coverage in certain regions restricts adoption in smaller hospitals and ambulatory centers. Healthcare providers in developing countries often rely on manual compression methods due to cost constraints. To overcome this challenge, manufacturers need to focus on cost-effective product development and collaborate with payers to improve reimbursement frameworks. Expanding access to affordable devices will be critical for market penetration in emerging economies.
Regional Analysis
North America
North America led the vascular closure device market in 2024 with over 40% share, driven by high prevalence of cardiovascular diseases and strong adoption of minimally invasive procedures. The U.S. remains the primary revenue contributor due to its advanced healthcare infrastructure and high procedural volumes of PCI and TAVR. Favorable reimbursement policies and rapid adoption of next-generation closure devices further support growth. Canada is also witnessing rising usage as healthcare systems invest in catheterization labs and outpatient facilities. Strong presence of leading manufacturers and continuous product launches strengthen regional dominance through innovation and clinical adoption.
Europe
Europe accounted for around 30% market share in 2024, supported by rising geriatric population and increasing prevalence of coronary artery disease. Germany, France, and the UK are key markets with significant procedural volumes and advanced hospital infrastructure. The region benefits from favorable government initiatives promoting minimally invasive surgeries and early discharge protocols. Adoption of bioabsorbable closure devices is growing rapidly in Western Europe due to strict safety regulations and preference for patient comfort. Eastern European countries are witnessing higher adoption as healthcare infrastructure improves, presenting opportunities for manufacturers to expand their distribution networks.
Asia-Pacific
Asia-Pacific captured nearly 20% of the market in 2024, emerging as the fastest-growing region. Rising healthcare investments in China, India, and Japan are driving procedural volumes for angioplasty and diagnostic interventions. Increasing awareness about vascular closure devices and government initiatives to improve access to advanced cardiovascular care are boosting demand. Growing medical tourism, particularly in India and Thailand, is fueling procedural growth. Local manufacturing and cost-effective product launches are enhancing affordability, supporting broader adoption across hospitals and ambulatory surgical centers. The region’s expanding patient pool and improving healthcare infrastructure make it a significant growth contributor.
Latin America
Latin America represented around 6% of global market share in 2024, driven by growing adoption of interventional cardiology procedures in Brazil, Mexico, and Argentina. Rising government spending on healthcare infrastructure and expansion of catheterization labs are boosting demand for vascular closure devices. However, cost sensitivity and limited reimbursement coverage remain barriers in some countries. Manufacturers are increasingly targeting the region through strategic partnerships with distributors and training programs for interventional cardiologists. Growth is expected to accelerate as healthcare systems modernize and focus shifts toward improving patient recovery and reducing hospital stays after vascular procedures.
Middle East & Africa
The Middle East & Africa accounted for nearly 4% of the market in 2024, with growth led by the Gulf Cooperation Council (GCC) countries. Rising prevalence of lifestyle-related cardiovascular diseases and improving access to advanced cardiac care are driving adoption. The UAE and Saudi Arabia are investing heavily in specialized cardiac centers, fueling procedural growth. Africa is witnessing slower adoption due to limited infrastructure and high device costs. However, increasing private sector participation and international collaborations are expected to boost availability and awareness of vascular closure devices in the coming years.
Market Segmentations:
By Product
- Passive Approximators
- Active Approximators
By Application
- Cardiac Interventions
- Cerebrovascular Interventions
- Peripheral Vascular Interventions
- Others
By End Use
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Cardiac Catherization Laboratories
By Geography
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the vascular closure device market is shaped by major players such as Teleflex Incorporated, Terumo Medical Corporation, Abbott, Haemonetics, Medtronic, Cardinal Health, Boston Scientific Corporation, Merit Medical, Cook Medical, and Meril Life. These companies focus on innovation, strategic collaborations, and global expansion to strengthen their market positions. Continuous product development, particularly in bioabsorbable and active closure devices, is a key strategy to meet growing demand for minimally invasive solutions. Mergers and acquisitions are common as players aim to expand product portfolios and geographic reach. Strong emphasis on clinical trials and regulatory approvals supports product reliability and boosts adoption among hospitals and ambulatory centers. Investment in physician training programs and post-market surveillance further enhances brand credibility. The competition remains intense, with companies striving to offer cost-effective and user-friendly devices that reduce procedure times and improve patient outcomes, creating opportunities for technology differentiation.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key Player Analysis
Recent Developments
- In August 2025, Boston Scientific issued an FDA early alert on WATCHMAN™ Access System use and safety.
- In July 2025, Medtronic enrolled the first patient in its Onyx™ Liquid Embolic IDE study in peripheral vasculature.
- In February 2024, Terumo Medical Corporation broke ground to expand Angio-Seal® production in Puerto Rico.
- In November 2023, Teleflex Incorporated began the ACCESS-MANTA™ registry enrolling up to 250 TAVR patients.
Report Coverage
The research report offers an in-depth analysis based on Product, Application, End Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
- The market will continue to grow steadily with increasing cardiovascular and peripheral interventions.
- Demand for bioabsorbable closure devices will rise due to safety and patient comfort benefits.
- Outpatient and same-day discharge procedures will drive higher adoption in ambulatory centers.
- Technological innovations will focus on faster deployment and reduced procedural time.
- Integration with imaging and navigation systems will enhance precision and operator confidence.
- Emerging markets will offer strong growth opportunities with improving healthcare infrastructure.
- Strategic partnerships and mergers will expand product portfolios and global presence.
- Training programs for physicians will boost adoption and improve procedural outcomes.
- Regulatory approvals for advanced devices will accelerate market penetration worldwide.
- Growing focus on cost-efficient solutions will increase usage in price-sensitive regions.
